Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 3/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4072097 | 0.77 | HSD11B1 (0.49) | HSD11B1ALDH1A1SMN1; SMN2NPC1LMNA | |
| SCHEMBL15007237 | 0.77 | HSD11B1 (0.52) | HSD11B1ALDH1A1SMN1; SMN2NPC1LMNA | |
| SCHEMBL5764736 | 0.75 | HSD11B1 (0.44) | HSD11B1ALDH1A1SMN1; SMN2NPC1LMNA | |
| SCHEMBL4817084 | 0.75 | MAOA (0.45) | HSD11B1ALDH1A1SMN1; SMN2NPC1LMNA | |
| SCHEMBL15006725 | 0.72 | SLC6A2 (0.41) | HSD11B1ALDH1A1SMN1; SMN2NPC1LMNA | |
| SCHEMBL5767477 | 0.71 | HSD11B1 (0.43) | HSD11B1ALDH1A1SMN1; SMN2NPC1LMNA | |
| SCHEMBL5766338 | 0.70 | HSD11B1 (0.45) | HSD11B1ALDH1A1SMN1; SMN2NPC1LMNA | |
| SCHEMBL5763351 | 0.70 | MAPK14 (0.56) | — | |
| SCHEMBL4824406 | 0.70 | MAPK14 (0.49) | — | |
| SCHEMBL4825071 | 0.69 | ALDH1A1 (0.48) | HSD11B1ALDH1A1SMN1; SMN2NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7321040-B2 | Triazolo-pyridines as anti-inflammatory compounds | PFIZER INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321040-B2 | Triazolo-pyridines as anti-inflammatory compounds | PFIZER INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321040-B2 | Triazolo-pyridines as anti-inflammatory compounds | PFIZER INC. (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1601672-B1 | TRIAZOLO-PYRIDINES AS ANTI-INFLAMMATORY COMPOUNDS | PFIZER PROD INC (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050075365-A1 | Novel triazolo-pyridines as anti-inflammatory compounds | PFIZER, INC. (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075365-A1 | Novel triazolo-pyridines as anti-inflammatory compounds | MAPK6, IL6, GRK6 | HSD11B1 3008/4885ALDH1A1 3595/4885SMN1; SMN2 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.